+22.6%
FITB vs GSK
+31.2%
-8.6%
-21.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | -1.9% | +1.7% | +0.2% |
| 7D | +0.6% | -1.8% | +2.4% | +1.0% |
| 30D | -4.7% | -2.2% | -2.6% | -4.4% |
| 3M | +6.7% | -1.8% | +8.5% | +6.9% |
| 6M | +12.6% | -10.6% | +23.2% | +14.4% |
| YTD | +19.1% | +4.4% | +14.7% | +19.9% |
| 1Y | +22.6% | +30.4% | -7.8% | +25.3% |
| All | +22.6% | +31.2% | -8.6% | +25.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling